Study to Evaluate the Efficacy of Tetracycline in Epidermolysis Bullosa
Randomised Double Blind Crossover Placebo Controlled Study to Evaluate the Efficacy of Tetracycline in Epidermolysis Bullosa
1 other identifier
interventional
N/A
0 countries
N/A
Brief Summary
Epidermolysis Bullosa(EB) is an inherited bullous disease. Tetracycline is believed to have anti inflammatory properties. 20 patients with EB older than 13 years will be treated for 4 months with tetracycline or placebo. After one month of wash out they will be treated for additional 4 m with placebo or tetracycline. The patients will be examined each month to estimate bulla formation,rate of healing .
Trial Health
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Primary Completion
Last participant's last visit for primary outcome
June 1, 2006
CompletedFirst Submitted
Initial submission to the registry
June 12, 2006
CompletedFirst Posted
Study publicly available on registry
June 13, 2006
CompletedOctober 28, 2020
October 1, 2020
June 12, 2006
October 27, 2020
Conditions
Outcome Measures
Primary Outcomes (1)
no of blisters
Interventions
Eligibility Criteria
You may qualify if:
- diagnosed as epidermolysis bullosa
- not pregnant
- active disease
- more than 5 bulla-
You may not qualify if:
- age less than 13
- known sensitivity to tetracyclin
- abnormal liver and kidney tests.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Design
- Study Type
- interventional
- Phase
- phase 4
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Purpose
- TREATMENT
- Intervention Model
- CROSSOVER
- Sponsor Type
- OTHER
Study Record Dates
First Submitted
June 12, 2006
First Posted
June 13, 2006
Primary Completion
June 1, 2006
Last Updated
October 28, 2020
Record last verified: 2020-10